Story
Sun Pharma Shares Decline Following US Plan for Steep Generic Drug Tariffs
Shares of Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) fell on Wednesday following a U.S. announcement detailing plans for steep future tariffs on generic drug imports. The stock declined 1.0% to close at ₹1,943, according to market data reported by Investing.com.
US Tariff Plan Unveiled
The sell-off was triggered by a statement from U.S. President Donald Trump on Tuesday evening, which outlined a multi-stage plan to levy significant duties on generics. The stated goal of the policy is to encourage the domestic manufacturing of pharmaceuticals within the United States.
The proposed tariff schedule is as follows:
- Generic drugs will remain exempt from import duties until August 2028.
- A 100% tariff will be imposed on applicable imports after that date.
- The rate is scheduled to increase further to 200% by 2029.
AdMarket Reaction and Outlook
The news created headwinds for the broader Indian pharmaceutical sector, a major exporter of generic drugs to the U.S. The pressure on drugmaking stocks contributed to a 0.6% decline in India's Nifty 50 index on Wednesday.
The tariff concerns emerge as Sun Pharma prepares to announce its June quarter earnings. According to the source, investors will be closely watching the results for any impact from other existing challenges to its export businesses.
Despite the near-term pressure, the long-term analyst view on Sun Pharma remains constructive. A consensus of 34 analysts cited by Investing.com rates the stock a "Buy" with an average 12-month price target of ₹2,047.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.